EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

ULBP2 Promotes Tumor Progression by Suppressing NKG2D-Mediated Anti-Tumor Immunity

Kohei Yamane, Kosuke Yamaguchi, Yasuhiko Teruya, Naomi Miyake, Yuji Nakayama, Takafumi Nonaka, Hiroki Chikumi, Akira Yamasaki iD

International Journal of Molecular Sciences · 24.03.2025 · 26 (7) · 2950

DOI: 10.3390/ijms26072950 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 24.03.2025. Verfasst von Kohei Yamane und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Respiratory Medicine and Rheumatology, Department of Multidisciplinary Internal Medicine, Faculty of Medicine, Tottori University, 36-1 N…. Hauptthemen laut MEDLINE: NK Cell Lectin-Like Receptor Subfamily K, Intercellular Signaling Peptides and Proteins, Melanoma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

UL-16 binding protein 2 (ULBP2), a human NKG2D ligand, has been identified as a poor prognostic factor in several cancers based on recent comprehensive analyses of immune-related genes using the Cancer Genome Atlas datasets. Despite its clinical significance, the functional role of ULBP2 in vivo remains largely unknown. In this study, we investigated the role of ULBP2 in modulating anti-tumor immunity using murine melanoma cell lines engineered to stably express surface-expressed or soluble ULBP2. Subcutaneous transplantation of ULBP2-expressing melanoma cells into syngeneic mice resulted in accelerated tumor growth, mediated by surface-expressed ULBP2, through the suppression of NKG2D-dependent immune responses. In vitro experiments revealed that sustained exposure to tumor-expressed ULBP2 reduced NKG2D expression and cytotoxic activity of splenocytes. In contrast, soluble ULBP2 did not significantly affect tumor growth or immune responses. These findings suggest that surface-expressed ULBP2 plays a pivotal role in tumor immune evasion and highlight its potential as a therapeutic target to enhance anti-tumor immunity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NK Cell Lectin-Like Receptor Subfamily KIntercellular Signaling Peptides and ProteinsMelanomaAnimalsMiceCell Line, TumorHumansDisease ProgressionMice, Inbred C57BLGPI-Linked Proteins

Stichwörter der Autor:innen

NK cellsNKG2DNKG2D ligandsULBP2cancer immunotherapyimmune evasiontumor immunology

Substanzen

NK Cell Lectin-Like Receptor Subfamily KULBP2 protein, humanIntercellular Signaling Peptides and ProteinsGPI-Linked ProteinsKlrk1 protein, mouse

Autor:innen und Institutionen

  • Division of Respiratory Medicine and Rheumatology, Department of Multidisciplinary Internal Medicine, Faculty of Medicine, Tottori University, 36-1 Nishi-cho, Yonago 683-8504, Japan.
  • Division of Radioisotope Science, Research Initiative Center, Organization for Research Initiative and Promotion, Tottori University, 86 Nishi-cho, Yonago 683-8503, Japan.
  • Division of Infectious Diseases, School of Medicine, Faculty of Medicine, Tottori University, 36-1 Nishi-cho, Yonago 683-8504, Japan.

ORCID-Profile: Akira Yamasaki

Förderung

  • Japan Agency for Medical Research and Development

Zitieren

APA

Yamane, K., Yamaguchi, K., Teruya, Y., Miyake, N., Nakayama, Y., Nonaka, T., Chikumi, H., & Yamasaki, A. (2025). ULBP2 Promotes Tumor Progression by Suppressing NKG2D-Mediated Anti-Tumor Immunity. International Journal of Molecular Sciences, 26(7), 2950. https://doi.org/10.3390/ijms26072950

Vancouver

Yamane K, Yamaguchi K, Teruya Y, Miyake N, Nakayama Y, Nonaka T, et al. ULBP2 Promotes Tumor Progression by Suppressing NKG2D-Mediated Anti-Tumor Immunity. International Journal of Molecular Sciences. 2025;26(7):2950. doi:10.3390/ijms26072950

BibTeX
@article{Yamane2025,
  author = {Yamane, Kohei and Yamaguchi, Kosuke and Teruya, Yasuhiko and Miyake, Naomi and Nakayama, Yuji and Nonaka, Takafumi and Chikumi, Hiroki and Yamasaki, Akira},
  title = {ULBP2 Promotes Tumor Progression by Suppressing NKG2D-Mediated Anti-Tumor Immunity},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {7},
  pages = {2950},
  doi = {10.3390/ijms26072950}
}
Kostenlos starten →